The Cardiovascular Medicine Conference is moderated by Richard W. Smalling, M.D., Ph.D., Jay Brent Sterling Professor of Cardiovascular Medicine and Co-Director, Division of Cardiology, University of Texas Medical School at Houston.
This conference may include discussion of commercial products and services.
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Dr. Richard W. Smalling, Cyberounds® Cardiovascular Medicine moderator, is the Jay Brent Sterling Professor of Cardiovascular Medicine and Director of Interventional Cardiovascular Medicine, Division of Cardiology, University of Texas Medical …School at Houston and the Memorial Hermann Heart and Vascular Institute. A native Texan, Dr. Smalling received his B.S. in Aerospace Engineering, M.S. in Bio-Medical Engineering, M.D. and Ph.D. from the University of Texas and did his residency training and cardiology fellowship at UCSD. Board certified in internal medicine, cardiovascular medicine, and interventional cardiology, Richard is the author of over 200 peer-reviewed articles and more than a dozen textbook chapters. He is on the editorial board of several cardiovascular journals. Dr. Smalling is an active investigator in clinical cardiology in the areas of thrombolysis and facilitated PCI for AMI, new interventional devices and percutaneous left ventricular assist devices. In addition to his clinical duties as an interventional cardiologist in patients with coronary, valvular adult congenital and peripheral vascular disease, Richard has an active animal physiology laboratory engaged in evaluation of mechanisms for prevention of reperfusion injury as well as new device development for coronary interventions and left ventricular assist.
Within the past 12 months, Dr. Smalling reports no commercial conflict of interest.
Last Update: 2/21/2021
